MedTrace Logo

Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy

NCT03595813 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2026-04-21

No results posted yet for this study

Summary

The development of Immune Checkpoint Blockade (ICB) is a revolution in medical oncology as ICB have changed the standard treatments of several metastatic tumor types. However, the response rate to ICB is low, and the biological bases for this response heterogeneity are poorly understood.

In the frame of Immunosup study, we will collect blood (at baseline, post infusion of ICB n°2/4/8 and at progression) and tumor samples (optional: at baseline and progression) from patients with locally advanced or metastatic cancer, treated with ICB, in order to determine if the dynamics of immunosuppressive actors (MDSC, TReg, Immunosuppressive cytokines) predicts response to these immunotherapies.

Conditions

  • Lung Cancer Metastatic
  • Locally Advanced Malignant Neoplasm
  • Non Hodgkin Lymphoma
  • Urologic Neoplasms

Interventions

PROCEDURE

Blood sample collection

Blood samples collection (5EDTA vials) at baseline, post infusion of ICB n°2/4/8 and at progression

PROCEDURE

Biopsy collection

Optional biopsy collection at baseline and progression

Sponsors & Collaborators

  • Cancer Research Center of Marseille

    collaborator OTHER

  • Institut Paoli-Calmettes

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-29
Primary Completion
2020-07-17
Completion
2025-06-25

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03595813 on ClinicalTrials.gov